Clinical trials
Lymphoma, B-Cell clinical trials
Below are recruiting lymphoma, b-cell clinical trials, each written for real people, not researchers. We’re tracking 534 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT06867536RecruitingPhase 2
Radiation plus glofitamab for relapsed large B-cell lymphoma with large tumors
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Wuhan, HubeiAges 18–75 - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT06863402RecruitingPhase 2
Study of two drugs for Richter transformation lymphoma
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Buffalo, New YorkAges 18 years+ - NCT06846463RecruitingPhase 2
Zanubrutinib for DLBCL with specific genetic changes
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
Richmond, VirginiaAges 18 years+ - NCT06852638RecruitingPhase 2
PET imaging for kidney cancer, lymphoma, and NPC
This study tests a new way to detect tumors by using a special injection that makes cancer cells visible on a PET scan. It may help people with renal cancer (especially clear cell type), lymphoma, or nasopharyngeal cancer.
ShanghaiAges 18–80 - NCT06854159RecruitingPhase 2
Odronextamab for diffuse large B-cell lymphoma before and after CAR T therapy
This trial tests a drug called odronextamab for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. It aims to see if the drug can help before and after a type of immunotherapy called CAR T-cell therapy.
Sacramento, CaliforniaAges 18 years+ - NCT06689917Recruiting
JY231 injection for relapsed B-cell lymphoma or leukemia
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
Wuhan, HubeiAges 18–75 - NCT06838832RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06829771RecruitingPhase 1/Phase 2
A new drug combined with standard chemo for large B-cell lymphoma
This trial is testing a new drug called TQB2825 given alongside standard chemotherapy (R-CHOP or GemOx) for people with diffuse large B-cell lymphoma (DLBCL) or a related type called grade 3b follicular lymphoma. The goal is to see if adding this new drug is safe and works better than standard treatment alone.
Bengbu, AnhuiAges 18–80 - NCT06830759Recruiting
Real-world study of epcoritamab for lymphoma
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18 years+ - NCT06830031RecruitingPhase 1
C402-CD19-CAR treatment for relapsed or refractory B-cell lymphoma
This trial tests a new CAR-T cell therapy called C402-CD19-CAR for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The treatment uses your own immune cells to target and kill cancer cells that have a protein called CD19 on their surface.
TianjinAges 18–75 - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT06835530RecruitingPhase 2
Rituximab and CC-99282 for older frail patients with large b-cell lymphoma
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
Alessandria, AlessandriaAges 80 years+ - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06682130RecruitingPhase 2
Glofitamab before stem cell transplant for relapsed DLBCL
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Suzhou, JiangsuAges 18–70 - NCT06822829Recruiting
Study of lymphoma that returned as slow-growing type
This study looks at people whose diffuse large B-cell lymphoma came back as a slower-growing lymphoma. Doctors want to understand how and why this happens, using medical records from diagnosis through follow-up.
Reggio EmiliaAges 18 years+ - NCT06820268RecruitingPhase 1
XS-04 for blood cancers that returned after treatment
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
BeijingAges 18–75 - NCT06806033RecruitingPhase 2
Glofitamab alone or with chemo for relapsed aggressive b-cell lymphoma
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
Anchorage, AlaskaAges 18 years+ - NCT06811272RecruitingPhase 2
Epcoritamab for older or frailer adults with large B-cell lymphoma
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
Boston, MassachusettsAges 18 years+ - NCT06803693RecruitingPhase 2
New drug combo for untreated large B-cell lymphoma
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06792253RecruitingPhase 3
BEBT-908 plus rituximab for relapsed large B-cell lymphoma
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
Beijing, Beijing MunicipalityAges 18–75 - NCT06788509Enrolling by invitationPhase 1
Continued treatment and safety monitoring after a parent study
This trial allows people who were already getting study treatment in a previous trial to keep receiving it and be monitored for safety. It is designed for those who have not had serious side effects or disease worsening.
Macquarie UniversityAges 18 years+ - NCT06785818Recruiting
Long-term follow-up of Kymriah patients in South Korea
This study follows patients in South Korea who have already received Kymriah (tisagenlecleucel) in a real-world setting. It aims to monitor their long-term health and any side effects over time.
Bundang Gu, Gyeonggi-doAges birth–100 years
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma, b-cell?
- Yes. Clin2 currently lists 534 recruiting lymphoma, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.